Primary spinal cord glioblastoma multiforme treated with XXXX .

@entity1 @entity2904 @entity4097 @entity2903 @entity463
UNASSIGNED: Since virtually no trials have evaluated the effectiveness of @entity2903 ( @entity2904 ) in the treatment of spinal cord (SC) @entity463 multiforme (GBM), we conducted a systematic review to evaluate its efficacy. Primary SC GBM is rare. Its management remains unclear, even though treatment guidelines have been established since 2005 for its cranial counterpart. We performed a medical subject heading search with the terms " @entity463 " and "primary @entity4097 , intramedullary". We stratified the papers into two groups according to the use of @entity2904 , and analyzed survival rates using the Kaplan-Meier method with a two-sided log-rank scale. The @entity2904 subgroup contained nine articles and a total of 19 @entity1 with primary SC GBM who were treated with adjuvant @entity2904 . The non- @entity2904 group consisted of 19 articles including 45 @entity1 who underwent other treatment modalities. The @entity2904 subgroup had an overall survival of 16months, compared to the non- @entity2904 group with a median overall survival of 10months. The difference between these two groups was not statistically significant (p=0.57). While this review did not demonstrate a statistically significant difference in long term survival between @entity1 with SC GBM treated with @entity2904 versus those not treated with @entity2904 , a slightly longer survival time was seen in the @entity2904 group. The small number of @entity1 is likely a contributing factor to the lack of statistical significance. Our analysis highlights the need for a multi-institutional, prospective, controlled study to evaluate the use of @entity2904 in the treatment of SC GBM.
